AIM: To investigate the candidate microRNA(miRNA), miR-221 as a novel biomarker for diabetic retinopathy(DR) in patients associated with type 2 diabetes(T2D).METHODS: The subjects involved were divided into four group...AIM: To investigate the candidate microRNA(miRNA), miR-221 as a novel biomarker for diabetic retinopathy(DR) in patients associated with type 2 diabetes(T2D).METHODS: The subjects involved were divided into four groups: healthy control(HC), no diabetic retinopathy(NDR), non-proliferative diabetic retinopathy(NPDR) and proliferative diabetic retinopathy(PDR) group. Serum miR-221 was validated by real-time quantitative reversetranscription polymerase chain reaction(qRT-PCR). Also, serum angiotensin II(Ang II) and vascular endothelial growth factor(VEGF) were examined by enzyme-linked immunosorbent assay. In addition, receiver operating characteristic(ROC) curve was performed to explore the diagnostic accuracy of miR-221, Ang Ⅱ and VEGF for DR in patients with T2D. Spearman’s rank correlation coefficient was executed to estimate the correlations of serum miR-221 with metabolic parameters and serum markers in patients with T2D.RESULTS: Primarily, serum miR-221, Ang Ⅱ and VEGF were increased significantly in T2D patients compared to HC participant respectively, and progressive up-regulated in NDR, NPDR and PDR groups(P<0.001). Additionally, miR-221 in serum was remarkably positively correlatedwith metabolic parameters such as glycated hemoglobin(r=0.310, P=0.002) and homeostasis model assessment for insulin resistance(r=0.413, P<0.001), as well as serum markers for instance Ang Ⅱ(r=0.667, P<0.001) and VEGF(r=0.499, P<0.001). Furthermore, serum miR-221(AUC, 0.894; 95%CI, 0.833-0.955; P<0.001), Ang Ⅱ(AUC, 0.888; 95%CI, 0.828-0.949; P<0.001) and VEGF(AUC, 0.785; 95%CI, 0.695-0.875; P<0.001) had evidently diagnostic efficiency in DR, and miR-221 is the most effective among them.CONCLUSION: Serum miR-221 as a potential biomarker could be related to not only occurrence but also progression for DR in patients with T2D. However, a prospective clinical trial is warranted.展开更多
目的探究Slug、胰岛素样生长因子ⅡmRNA结合蛋白3(insulin-like growth factorⅡmRNA-binding protein 3,IMP3)和微小RNA(microRNA,miR)-221在食管胃交界腺癌(adenocarcinoma of the esophagogastric junction,AEG)的表达及其与E-钙黏蛋...目的探究Slug、胰岛素样生长因子ⅡmRNA结合蛋白3(insulin-like growth factorⅡmRNA-binding protein 3,IMP3)和微小RNA(microRNA,miR)-221在食管胃交界腺癌(adenocarcinoma of the esophagogastric junction,AEG)的表达及其与E-钙黏蛋白(E-cadherin)的关系。方法选取2017年12月至2019年6月邯郸市第一医院收集的AEG患者100例作为研究对象。收集同期体检者正常胃组织50例作为健康组。经过手术或全身PET-CT检测AEG转移情况。通过qPCR检测组织中miR-221的表达水平。通过免疫组化染色检测组织中E-cadherin、Slug、IMP3的表达。结果AEG组织中Slug、IMP3阳性率及miR-221相对表达量均显著高于健康组织(P<0.05)。性别、年龄及肿瘤大小对AEG组织中Slug、IMP3和miR-221的影响不大(P>0.05)。Ⅲ/Ⅳ分期、出现局部浸润、淋巴转移、远端转移患者的AEG组织中Slug、IMP3阳性率及miR-221显著升高(P<0.05)。且E-cadherin阳性组织中Slug、IMP3和miR-221显著低于E-cadherin阴性(P<0.05)。结论Slug、IMP3和miR-221在AEG中均过表达,与AEG转移有关,且与E-cadherin水平呈负相关,提示Slug、IMP3和miR-221可作为AEG的生物标志物。展开更多
基金National Natural Science Foundation of China (No.81371045No.81570866)+3 种基金Science and Technology Program of Liaoning Province,China (No.201002196No.2013225049)Science and Technology Program of Shenyang Municipality,China (No.F13-221-9-37No.18-014-4-41)
文摘AIM: To investigate the candidate microRNA(miRNA), miR-221 as a novel biomarker for diabetic retinopathy(DR) in patients associated with type 2 diabetes(T2D).METHODS: The subjects involved were divided into four groups: healthy control(HC), no diabetic retinopathy(NDR), non-proliferative diabetic retinopathy(NPDR) and proliferative diabetic retinopathy(PDR) group. Serum miR-221 was validated by real-time quantitative reversetranscription polymerase chain reaction(qRT-PCR). Also, serum angiotensin II(Ang II) and vascular endothelial growth factor(VEGF) were examined by enzyme-linked immunosorbent assay. In addition, receiver operating characteristic(ROC) curve was performed to explore the diagnostic accuracy of miR-221, Ang Ⅱ and VEGF for DR in patients with T2D. Spearman’s rank correlation coefficient was executed to estimate the correlations of serum miR-221 with metabolic parameters and serum markers in patients with T2D.RESULTS: Primarily, serum miR-221, Ang Ⅱ and VEGF were increased significantly in T2D patients compared to HC participant respectively, and progressive up-regulated in NDR, NPDR and PDR groups(P<0.001). Additionally, miR-221 in serum was remarkably positively correlatedwith metabolic parameters such as glycated hemoglobin(r=0.310, P=0.002) and homeostasis model assessment for insulin resistance(r=0.413, P<0.001), as well as serum markers for instance Ang Ⅱ(r=0.667, P<0.001) and VEGF(r=0.499, P<0.001). Furthermore, serum miR-221(AUC, 0.894; 95%CI, 0.833-0.955; P<0.001), Ang Ⅱ(AUC, 0.888; 95%CI, 0.828-0.949; P<0.001) and VEGF(AUC, 0.785; 95%CI, 0.695-0.875; P<0.001) had evidently diagnostic efficiency in DR, and miR-221 is the most effective among them.CONCLUSION: Serum miR-221 as a potential biomarker could be related to not only occurrence but also progression for DR in patients with T2D. However, a prospective clinical trial is warranted.
文摘目的探究Slug、胰岛素样生长因子ⅡmRNA结合蛋白3(insulin-like growth factorⅡmRNA-binding protein 3,IMP3)和微小RNA(microRNA,miR)-221在食管胃交界腺癌(adenocarcinoma of the esophagogastric junction,AEG)的表达及其与E-钙黏蛋白(E-cadherin)的关系。方法选取2017年12月至2019年6月邯郸市第一医院收集的AEG患者100例作为研究对象。收集同期体检者正常胃组织50例作为健康组。经过手术或全身PET-CT检测AEG转移情况。通过qPCR检测组织中miR-221的表达水平。通过免疫组化染色检测组织中E-cadherin、Slug、IMP3的表达。结果AEG组织中Slug、IMP3阳性率及miR-221相对表达量均显著高于健康组织(P<0.05)。性别、年龄及肿瘤大小对AEG组织中Slug、IMP3和miR-221的影响不大(P>0.05)。Ⅲ/Ⅳ分期、出现局部浸润、淋巴转移、远端转移患者的AEG组织中Slug、IMP3阳性率及miR-221显著升高(P<0.05)。且E-cadherin阳性组织中Slug、IMP3和miR-221显著低于E-cadherin阴性(P<0.05)。结论Slug、IMP3和miR-221在AEG中均过表达,与AEG转移有关,且与E-cadherin水平呈负相关,提示Slug、IMP3和miR-221可作为AEG的生物标志物。
